Want to see TSE:BIOV full AI Analyst Report?
BIOV Stock Chart & Stats
C$0.07
C$0.01(16.67%)
At close: 4:00 PM EDT
C$0.07
C$0.01(16.67%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.30
Previous CloseN/A
Volume13.47K
Average Volume (3M)0.00
Market Cap
C$2.04M
Enterprise ValueC$5.96M
Total Cash (Recent Filing)C$4.08K
Total Debt (Recent Filing)C$133.72K
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding44,094,670
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-7.14
Price to Sales (P/S)0.00
P/FCF Ratio-4.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BioVaxys Technology News
BIOV FAQ
What was BioVaxys Technology’s price range in the past 12 months?
BioVaxys Technology lowest stock price was C$0.03 and its highest was C$0.30 in the past 12 months.
What is BioVaxys Technology’s market cap?
BioVaxys Technology’s market cap is C$2.04M.
When is BioVaxys Technology’s upcoming earnings report date?
BioVaxys Technology’s upcoming earnings report date is Apr 01, 2027 which is in 169 days.
How were BioVaxys Technology’s earnings last quarter?
BioVaxys Technology released its earnings results on Oct 02, 2025. The company reported -C$0.031 earnings per share for the quarter.
Is BioVaxys Technology overvalued?
According to Wall Street analysts BioVaxys Technology’s price is currently Overvalued.
Does BioVaxys Technology pay dividends?
BioVaxys Technology does not currently pay dividends.
What is BioVaxys Technology’s EPS estimate?
BioVaxys Technology’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BioVaxys Technology have?
BioVaxys Technology has 44,094,670 shares outstanding.
What happened to BioVaxys Technology’s price movement after its last earnings report?
BioVaxys Technology reported an EPS of -C$0.031 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of BioVaxys Technology?
Currently, no hedge funds are holding shares in TSE:BIOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BioVaxys Technology
BioVaxys Technology Corp. is a clinical-stage biotechnology company specializing in the development of vaccine platforms designed to combat both viral infections and cancer. The company's pipeline includes BVX-0320, a single-strain vaccine for SARS-CoV-2, and BVX-0918A, an experimental haptenized tumor cell vaccine targeting ovarian cancer. Additionally, BioVaxys offers CoviDTH, an immunodiagnostic tool to detect immune system activity in SARS-CoV-2-exposed patients. Further initiatives encompass Papilocare, aimed at HPV-dependent cervical lesions, along with BVX-0918C for cervical cancer, the HPV viral vaccine BVX-0204, and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys has established strategic collaborations, such as a bioproduction agreement with WuXi Biologics Limited to manufacture SARS-CoV-2 s-proteins crucial for BVX-0320 and CoviDTH. It also holds a research partnership with The Ohio State University, Wexner School of Medicine, focusing on BVX-0320, and has engaged Bioanalytical Systems, Inc. for preclinical toxicology evaluations of its CoviDTH immunodiagnostic. The company is headquartered in Vancouver, Canada.
Technical Analysis
Arch Biopartners
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
Vaxil Bio
―
Defence Therapeutics
―